1. Home
  2. LEGN vs CELH Comparison

LEGN vs CELH Comparison

Compare LEGN & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CELH
  • Stock Information
  • Founded
  • LEGN 2014
  • CELH 2004
  • Country
  • LEGN United States
  • CELH United States
  • Employees
  • LEGN N/A
  • CELH N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CELH Beverages (Production/Distribution)
  • Sector
  • LEGN Health Care
  • CELH Consumer Staples
  • Exchange
  • LEGN Nasdaq
  • CELH Nasdaq
  • Market Cap
  • LEGN 6.3B
  • CELH 15.7B
  • IPO Year
  • LEGN 2020
  • CELH N/A
  • Fundamental
  • Price
  • LEGN $32.07
  • CELH $64.39
  • Analyst Decision
  • LEGN Buy
  • CELH Strong Buy
  • Analyst Count
  • LEGN 11
  • CELH 18
  • Target Price
  • LEGN $71.90
  • CELH $62.61
  • AVG Volume (30 Days)
  • LEGN 1.4M
  • CELH 5.4M
  • Earning Date
  • LEGN 11-11-2025
  • CELH 11-05-2025
  • Dividend Yield
  • LEGN N/A
  • CELH N/A
  • EPS Growth
  • LEGN N/A
  • CELH N/A
  • EPS
  • LEGN N/A
  • CELH 0.39
  • Revenue
  • LEGN $796,838,000.00
  • CELH $1,666,480,000.00
  • Revenue This Year
  • LEGN $70.27
  • CELH $84.05
  • Revenue Next Year
  • LEGN $50.28
  • CELH $29.58
  • P/E Ratio
  • LEGN N/A
  • CELH $162.89
  • Revenue Growth
  • LEGN 74.75
  • CELH 11.85
  • 52 Week Low
  • LEGN $27.34
  • CELH $21.10
  • 52 Week High
  • LEGN $47.79
  • CELH $66.74
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 41.09
  • CELH 65.11
  • Support Level
  • LEGN $30.77
  • CELH $59.73
  • Resistance Level
  • LEGN $34.80
  • CELH $66.74
  • Average True Range (ATR)
  • LEGN 1.49
  • CELH 2.27
  • MACD
  • LEGN 0.16
  • CELH 0.44
  • Stochastic Oscillator
  • LEGN 28.04
  • CELH 71.16

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CELH Celsius Holdings Inc.

Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.

Share on Social Networks: